FI105270B - Menetelmä terapeuttisesti käyttökelpoisten oktahydro-1H-1-pyrindiini-4,5,6,7-terolien valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten oktahydro-1H-1-pyrindiini-4,5,6,7-terolien valmistamiseksi Download PDF

Info

Publication number
FI105270B
FI105270B FI941259A FI941259A FI105270B FI 105270 B FI105270 B FI 105270B FI 941259 A FI941259 A FI 941259A FI 941259 A FI941259 A FI 941259A FI 105270 B FI105270 B FI 105270B
Authority
FI
Finland
Prior art keywords
formula
compound
octahydro
hydrogen
bno
Prior art date
Application number
FI941259A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI941259A0 (fi
FI941259A (fi
Inventor
Norton P Peet
Robert A Farr
Mohinder S Kang
Sai P Sunkara
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Publication of FI941259A0 publication Critical patent/FI941259A0/fi
Publication of FI941259A publication Critical patent/FI941259A/fi
Application granted granted Critical
Publication of FI105270B publication Critical patent/FI105270B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Indole Compounds (AREA)
FI941259A 1991-09-18 1994-03-17 Menetelmä terapeuttisesti käyttökelpoisten oktahydro-1H-1-pyrindiini-4,5,6,7-terolien valmistamiseksi FI105270B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US76157991A 1991-09-18 1991-09-18
US76157991 1991-09-18
US07/893,171 US5262425A (en) 1991-09-18 1992-06-03 α-mannosidase inhibitors
US89317192 1992-06-03
US9206707 1992-08-10
PCT/US1992/006707 WO1993005781A1 (en) 1991-09-18 1992-08-10 Novel alpha-mannosidase inhibitors

Publications (3)

Publication Number Publication Date
FI941259A0 FI941259A0 (fi) 1994-03-17
FI941259A FI941259A (fi) 1994-03-17
FI105270B true FI105270B (fi) 2000-07-14

Family

ID=27117010

Family Applications (1)

Application Number Title Priority Date Filing Date
FI941259A FI105270B (fi) 1991-09-18 1994-03-17 Menetelmä terapeuttisesti käyttökelpoisten oktahydro-1H-1-pyrindiini-4,5,6,7-terolien valmistamiseksi

Country Status (15)

Country Link
US (1) US5262425A (ko)
EP (1) EP0641327B1 (ko)
JP (1) JP3226173B2 (ko)
KR (1) KR100244012B1 (ko)
AT (1) ATE175960T1 (ko)
AU (1) AU659486B2 (ko)
CA (1) CA2116224C (ko)
DE (1) DE69228259T2 (ko)
DK (1) DK0641327T3 (ko)
ES (1) ES2127758T3 (ko)
FI (1) FI105270B (ko)
GR (1) GR3029745T3 (ko)
HU (1) HU216789B (ko)
NO (1) NO300372B1 (ko)
WO (1) WO1993005781A1 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773239A (en) * 1993-10-19 1998-06-30 Mount Sinai Hospital Corporation. Mannosidase inhibitors, process for their preparation and their use as therapeutic agents
US5650413A (en) * 1995-06-07 1997-07-22 Glycodesign Inc. Derivatives of swainsonine, processes for their preparation and their use as therapeutic agents
CA2267412A1 (en) * 1996-10-01 1998-04-09 Glycodesign Inc. Novel 3, 5, and/or 6 substituted analogues of swainsonine, processes for their preparation and their use as therapeutic agents
CA2286766A1 (en) 1997-04-15 1998-10-22 Glycodesign Inc. Alkaloid halide salts of swainsonine and methods of use
US6245316B1 (en) 1997-10-08 2001-06-12 David Platt Enhancement of delivery of radioimaging and radioprotective agents
CA2307595A1 (en) * 1997-10-24 1999-05-06 Glycodesign Inc. Synthesis of swainsonine salts

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031102A (en) * 1972-10-21 1977-06-21 John Wyeth & Brother Limited Cyclopenteno[b]pyridine derivatives
GB2088860B (en) * 1980-12-09 1984-05-23 Wyeth John & Brother Ltd Process for preparing ring-fused pyridine derivatives

Also Published As

Publication number Publication date
ATE175960T1 (de) 1999-02-15
EP0641327B1 (en) 1999-01-20
WO1993005781A1 (en) 1993-04-01
CA2116224A1 (en) 1993-04-01
KR100244012B1 (ko) 2000-03-02
HUT70527A (en) 1995-10-30
DK0641327T3 (da) 1999-09-13
US5262425A (en) 1993-11-16
HU9400787D0 (en) 1994-06-28
DE69228259D1 (de) 1999-03-04
NO300372B1 (no) 1997-05-20
NO940972L (no) 1994-03-17
GR3029745T3 (en) 1999-06-30
EP0641327A1 (en) 1995-03-08
EP0641327A4 (en) 1994-06-01
AU659486B2 (en) 1995-05-18
AU2477192A (en) 1993-04-27
FI941259A0 (fi) 1994-03-17
JPH06510785A (ja) 1994-12-01
JP3226173B2 (ja) 2001-11-05
CA2116224C (en) 2003-06-03
DE69228259T2 (de) 1999-06-02
HU216789B (hu) 1999-08-30
ES2127758T3 (es) 1999-05-01
FI941259A (fi) 1994-03-17
NO940972D0 (no) 1994-03-17

Similar Documents

Publication Publication Date Title
EP0708085B1 (en) Antiviral ethers of aspartate protease substrate isosteres
US10294246B2 (en) Substituted boronic acids and boronate esters as immunoproteasome inhibitors
EA005817B1 (ru) Производные гексагидро-7-1h-азепин-2-илгексановой (или гексеновой) кислоты в качестве ингибиторов индуцибельной синтазы оксида азота
CA2903483A1 (en) Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders
US8258321B2 (en) Beta-lactone compounds
KR20190129968A (ko) 기생충성 질환의 치료를 위한 화합물 및 방법
JP2021531310A (ja) ボロン酸誘導体
FI105270B (fi) Menetelmä terapeuttisesti käyttökelpoisten oktahydro-1H-1-pyrindiini-4,5,6,7-terolien valmistamiseksi
US11434198B2 (en) Compounds and methods for the treatment of neurodegenerative diseases
KR100894237B1 (ko) 항미생물제로서의엔-설포닐-4-메틸렌아미노-3-하이드록시-2-피리돈
MXPA06000294A (es) Compuestos que tienen actividad contra el virus de la hepatitis c y procedimiento para producirlo.
US10464883B2 (en) Compounds and methods for the treatment of neurodegenerative diseases
EP3353163B1 (en) 2,3,4,5-tetrahydropyridin-6-amine derivatives
US20220144836A1 (en) Novel synthetic options towards the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one
CA2040058C (en) Alpha-mannosidase and fucosidase inhibitors
US5240707A (en) Alpha-mannosidase and fucosidase inhibitors
KR20220139752A (ko) 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 싸이오카보닐 화합물 및 이를 포함하는 약제학적 조성물
JP2009520813A (ja) カルバメート系抗生物質
EP1387841A1 (fr) Nouveaux derives d'azole ou de triazole, leur procede de preparation et leur application comme fongicides
KR101881115B1 (ko) 신규 2-치환된 테트라하이드로피란 또는 2-치환된 테트라하이드로퓨란 유도체 화합물, 이의 제조방법 및 이의 용도
CA3102497A1 (en) Open-ring fatty acid compound having anti-cancer activity
RU2780118C2 (ru) Производные иминомочевины
EP0949238A1 (en) Substituted propionyl derivatives
WO1998042700A1 (fr) Derives de n-(arginyl)benzenesulfonamide et leur utilisation comme agents antithrombotiques
WO2022040788A1 (en) Open-ring and lactone derivatives of unsaturated trihydroxy c-18 fatty acids and pharmaceutical compositions thereof having anti-cancer activity